1508 related articles for article (PubMed ID: 16971734)
1. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
3. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P
Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
[No Abstract] [Full Text] [Related]
4. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
Jahanzeb M
Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
7. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
10. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
Belkacémi Y; Gligorov J; Mauriac L; Azria D
Bull Cancer; 2006 Oct; 93(10):991-9. PubMed ID: 17074658
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
12. Use of trastuzumab for the treatment of early stage breast cancer.
Braga S; dal Lago L; Bernard C; Cardoso F; Piccart M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1153-64. PubMed ID: 16925482
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
14. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
Smith I; Procter M; Gelber RD; Guillaume S; Feyereislova A; Dowsett M; Goldhirsch A; Untch M; Mariani G; Baselga J; Kaufmann M; Cameron D; Bell R; Bergh J; Coleman R; Wardley A; Harbeck N; Lopez RI; Mallmann P; Gelmon K; Wilcken N; Wist E; Sánchez Rovira P; Piccart-Gebhart MJ;
Lancet; 2007 Jan; 369(9555):29-36. PubMed ID: 17208639
[TBL] [Abstract][Full Text] [Related]
15. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA
Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447
[TBL] [Abstract][Full Text] [Related]
16. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
Eniu A
J BUON; 2007 Sep; 12 Suppl 1():S119-26. PubMed ID: 17935269
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer].
Huober J; Jackisch C; Untch M; Möbus V; Wallwiener D; Kaufmann M; Minkwitz G
Zentralbl Gynakol; 2006 Feb; 128(1):30-7. PubMed ID: 16450285
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab (herceptin) for early-stage breast cancer.
Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and economic issues in adjuvant chemotherapy for HER-2 positive breast cancer].
Martins SJ; Yamamoto CA
Rev Assoc Med Bras (1992); 2008; 54(6):494-9. PubMed ID: 19197525
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]